All In MedTech

FDA Clearance Tracker · P200029

TheraSphere

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Mar 17, 2021 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Mar 17, 2021

Approved

Time to decision

266 days

Received Jun 24, 2020. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P200029
Device name
TheraSphere
Applicant location
Marborough, MA
Received
Jun 24, 2020
Decided
Mar 17, 2021
Decision
Approved
Supplements
14 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code NAW

FDA's approval statement

As written in FDA's record.

Approval for TheraSphereTM. This device is indicated for use as selective internal radiation therapy (SIRT) for local tumor control of solitary tumors (1-8 cm in diameter), in patients with unresectable hepatocellular carcinoma (HCC), Child-Pugh Score A cirrhosis, well-compensated liver function, no macrovascular invasion, and good performance status.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code NAW. The earliest in FDA's data is P990065, decided Mar 5, 2002.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Boston Scientific Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.